




## REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia

### Descrizione

COMUNICATO STAMPA â?? CONTENUTO PROMOZIONALE

MOTIV BTK randomized trial met primary efficacy endpoint, with early and sustained clinical benefit in a complex patient population

SAN DIEGO, April 21, 2026 /PRNewswire/ â?? REVA Medical, LLC today announced primary endpoint results from the MOTIV BTK randomized pivotal clinical trial evaluating the MOTIVÂ® sirolimus-eluting bioresorbable vascular scaffold in patients with critical limb-threatening ischemia (CLTI). The results were presented today at the Charing Cross International Symposium in London, UK.

The MOTIV BTK trial met both its primary safety and efficacy endpoints, demonstrating that the MOTIV scaffold provides a statistically significant improvement in clinical outcomes compared to the current standard of care, balloon angioplasty.

Results of the one-year MOTIV BTK clinical trial showed:

The trial enrolled a complex CLTI population, including a high proportion of Rutherford 5 patients and challenging lesion characteristics representative of real-world disease.

â??Patients with critical limb-threatening ischemia have limited treatment options and face a high risk of limb loss and mortality,â?• said Ehrin Armstrong, MD, MSc, Interventional Cardiology and Vascular Intervention HCA HealthOne Swedish Medical Center, Denver, Colorado and Principal Investigator of the MOTIV BTK trial. â??The MOTIV data demonstrate a meaningful and statistically significant improvement over balloon angioplasty, particularly in a complex patient population.â?•

CLTI is the most severe form of peripheral artery disease, affecting millions of patients worldwide and often leading to severe pain, non-healing wounds, and amputation. Balloon angioplasty remains a primary treatment option in the U.S., but long-term vessel patency remains a significant challenge. The MOTIV bioresorbable scaffold is designed to open blocked arteries, support the vessel during healing, and then gradually be reabsorbed by the body, restoring the vessel without leaving a permanent

implant.

In addition, the MOTIV scaffold is designed with full radiopacity, enabling physicians to directly visualize the scaffold during implantation and optimize placement in complex below-the-knee anatomy.

“The MOTIV trial results represent a significant advancement for patients in the treatment of below-the-knee disease,” said Jeffrey Anderson, President and Chief Executive Officer of REVA Medical. “The magnitude of benefit observed, along with early and sustained clinical improvement, reinforces the potential of bioresorbable scaffold technology to address a critical unmet need in this high-risk patient population.”

The MOTIV BTK trial is a prospective, multicenter, randomized controlled study evaluating the safety and efficacy of the MOTIV scaffold compared to balloon angioplasty in patients with infrapopliteal arterial disease.

CAUTION: Investigational device. Limited by Federal (U.S.) law to investigational use only.

#### About REVA Medical

REVA Medical is a medical device company focused on developing and commercializing bioresorbable polymer technologies for vascular applications. The company’s proprietary Tyrocore® polymer platform combines strength, radiopacity, and controlled degradation, enabling innovative solutions such as the MOTIV® bioresorbable scaffold for peripheral artery disease.

Douglas Henson REVA Medical, LLC +1 858-966-3024 email us here Visit us on social media: LinkedIn

View original content: <https://www.prnewswire.com/news-releases/rev-medical-announces-positive-motiv-btk-trial-results-showing-superiority-in-patients-with-critical-limb-threatening-ischemia-302748136.html>

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

–

[immediapress/pr-newswire](https://www.immediapress.com/pr-newswire)

#### Categoria

1. Comunicati

#### Tag

1. ImmediaPress

#### Data di creazione

---

Aprile 21, 2026

**Autore**  
redazione

*default watermark*